Trial Profile
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Z-Butylidenephthalide (Primary) ; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Everfront Biotech
- 16 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 16 Jan 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Apr 2023.
- 16 Jan 2023 Status changed from recruiting to active, no longer recruiting.